As mentioned in a previous Newsletter, DANSK BIOTEK has joined the newly established Genstartsteam (Restart Teams) for Life Science & Biotech, headed by Novo Nordisk’s Lars Fruergaard. The initiative has a common goal of supporting the Danish export and get the country financially restarted as efficiently as possible.
In connection with the initial work in the Restart Team, Novo Nordisk asked Damvad Analytics to prepare a report on the growth opportunities for the life science industry in Denmark. The report (in Danish) has now been published and can be found on Novo Nordisk’s website:
It is abundantly clear that the life science industry has a lot of growth potential, which can support our country’s economy and welfare. We in DANSK BIOTEK keep pointing out the obvious: Biotech is the primary source for new products in the life science industry, so the expected growth can only happen, if Denmark ensures that it is attractive to build and finance biotech companies here.
Hans Schambye, Chairman, DANSK BIOTEK